NeuroPace (NPCE) News Today $13.90 +0.29 (+2.13%) Closing price 02/4/2025 04:00 PM EasternExtended Trading$13.90 0.00 (0.00%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9thFebruary 3 at 4:13 PM | globenewswire.comFY2025 EPS Estimates for NeuroPace Decreased by AnalystFebruary 2 at 1:49 AM | americanbankingnews.comNeuroPace (NASDAQ:NPCE) Price Target Raised to $17.00 at Wells Fargo & CompanyFebruary 1, 2025 | americanbankingnews.comNeuroPace FY2025 EPS Estimate Decreased by Cantor FitzgeraldNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for NeuroPace in a report issued on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.80) pJanuary 31, 2025 | marketbeat.comLeerink Partnrs Estimates NeuroPace FY2029 EarningsJanuary 31, 2025 | americanbankingnews.comNeuroPace price target raised to $17 from $13 at Wells FargoJanuary 30, 2025 | markets.businessinsider.comWells Fargo & Company Forecasts Strong Price Appreciation for NeuroPace (NASDAQ:NPCE) StockWells Fargo & Company raised their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday.January 30, 2025 | marketbeat.comNeuroPace, Inc.: NeuroPace Issues 2025 Financial Guidance TargetsJanuary 30, 2025 | finanznachrichten.deLeerink Partnrs Comments on NeuroPace FY2029 EarningsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for NeuroPace in a research report issued to clients and investors on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky expects that the company willJanuary 30, 2025 | marketbeat.comNeuroPace: Strategic Growth and Market Expansion Drive Positive OutlookJanuary 30, 2025 | markets.businessinsider.comNeuroPace sees FY25 revenue $92M-$96M, consensus $91.23MJanuary 29, 2025 | markets.businessinsider.comNeuroPace's SWOT analysis: epilepsy device maker's stock poised for growthJanuary 29, 2025 | msn.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells 3,200 Shares of StockJanuary 29, 2025 | insidertrades.comNeuropace chief medical officer Morrell sells $48,032 in stockJanuary 28, 2025 | msn.comNeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) insider Martha Morrell sold 3,200 shares of the business's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the transaction, the insider now directly owns 87,062 shares in the company, valued at approximately $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.January 28, 2025 | marketbeat.comNeuroPace Issues 2025 Financial Guidance TargetsJanuary 28, 2025 | globenewswire.comLake Street Remains a Buy on NeuroPace (NPCE)January 24, 2025 | markets.businessinsider.comCantor Fitzgerald Comments on NeuroPace FY2025 EarningsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for NeuroPace in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($0.79January 23, 2025 | marketbeat.comNeuroPace initiated with a Buy at UBSJanuary 22, 2025 | markets.businessinsider.comUBS Initiates Coverage of NeuroPace (NPCE) with Buy RecommendationJanuary 22, 2025 | msn.comNeuroPace (NASDAQ:NPCE) Now Covered by UBS GroupUBS Group started coverage on NeuroPace in a research report on Tuesday. They set a "buy" rating and a $17.00 price objective on the stock.January 21, 2025 | marketbeat.comUBS sees upside for NeuroPace shares with 22% CAGR and market expansion driversJanuary 21, 2025 | msn.comKck Ltd. Purchases Shares of 5,270,845 NeuroPace, Inc. (NASDAQ:NPCE)Kck Ltd. acquired a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,270,845 shares of the company's stock, valued at approximately $58,January 19, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by AnalystsNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the companyJanuary 14, 2025 | marketbeat.comPromising Outlook for NeuroPace: Revenue Beats, Clinical Progress, and Growth CatalystsJanuary 13, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)January 10, 2025 | markets.businessinsider.comNeuroPace reports sees Q4 revenue $21M-$21.5M, consensus $20.91MJanuary 9, 2025 | markets.businessinsider.comNeuroPace, Inc.: NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business UpdatesJanuary 9, 2025 | finanznachrichten.deNeuroPace narrows FY24 revenue view to $79.4M-$79.9M from $78M-$80MJanuary 9, 2025 | markets.businessinsider.comNeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business UpdatesJanuary 8, 2025 | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued aDecember 20, 2024 | marketbeat.comNeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | globenewswire.comNeuroPace: Undervalued Innovator in the Drug-Resistant Epilepsy Market with Promising Long-Term GrowthDecember 17, 2024 | markets.businessinsider.comNeuroPace (NASDAQ:NPCE) Given New $14.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday.December 17, 2024 | marketbeat.comNeuroPace (NASDAQ:NPCE) Trading Up 4% - Should You Buy?NeuroPace (NASDAQ:NPCE) Trading Up 4% - What's Next?December 17, 2024 | marketbeat.comNeuroPace to Host Investor Day on January 28th in New York CityDecember 12, 2024 | globenewswire.comLake Street Sticks to Its Buy Rating for NeuroPace (NPCE)December 6, 2024 | markets.businessinsider.comNeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual MeetingDecember 4, 2024 | globenewswire.comNeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut SyndromeDecember 3, 2024 | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from AnalystsNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendatiNovember 25, 2024 | marketbeat.comStrong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market AdvancementsNovember 22, 2024 | markets.businessinsider.comNeuroPace FY2024 EPS Forecast Raised by Cantor FitzgeraldNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of NeuroPace in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that tNovember 18, 2024 | marketbeat.comNeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy RatingNovember 15, 2024 | markets.businessinsider.comNeuroPace FY2024 EPS Estimate Boosted by Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings estimates for NeuroPace in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($1.03) forNovember 15, 2024 | marketbeat.comNeuroPace price target lowered to $13 from $15 at Wells FargoNovember 13, 2024 | markets.businessinsider.comNeuroPace’s Strong Financial Performance and Strategic Advancements Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comNeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comNeuroPace raises FY24 revenue view to $78M-$80M from $76M-$78MNovember 13, 2024 | markets.businessinsider.comNeuroPace, Inc. Reports Strong Q3 2024 ResultsNovember 13, 2024 | markets.businessinsider.comNeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...November 13, 2024 | finance.yahoo.com Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Media Mentions By Week NPCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.540.44▲Average Medical News Sentiment NPCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼202▲NPCE Articles Average Week Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cadre News InMode News BioLife Solutions News RxSight News Artivion News MiMedx Group News Liquidia News Pulse Biosciences News Embecta News Paragon 28 News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
